HK1199021A1 - Quinazoline compounds as serine threonine kinase inhibitors - Google Patents
Quinazoline compounds as serine threonine kinase inhibitorsInfo
- Publication number
- HK1199021A1 HK1199021A1 HK14112451.1A HK14112451A HK1199021A1 HK 1199021 A1 HK1199021 A1 HK 1199021A1 HK 14112451 A HK14112451 A HK 14112451A HK 1199021 A1 HK1199021 A1 HK 1199021A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- kinase inhibitors
- threonine kinase
- serine threonine
- quinazoline compounds
- quinazoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161515165P | 2011-08-04 | 2011-08-04 | |
| PCT/US2012/049551 WO2013020062A1 (en) | 2011-08-04 | 2012-08-03 | Quinazoline compounds as serine/threonine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1199021A1 true HK1199021A1 (en) | 2015-06-19 |
Family
ID=47003195
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14112451.1A HK1199021A1 (en) | 2011-08-04 | 2014-12-10 | Quinazoline compounds as serine threonine kinase inhibitors |
| HK14112740.2A HK1199248A1 (zh) | 2011-08-04 | 2014-12-19 | 作為絲氨酸/蘇氨酸激酶抑制劑的喹唑啉化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14112740.2A HK1199248A1 (zh) | 2011-08-04 | 2014-12-19 | 作為絲氨酸/蘇氨酸激酶抑制劑的喹唑啉化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9187462B2 (xx) |
| EP (1) | EP2739618B1 (xx) |
| JP (1) | JP6097289B2 (xx) |
| KR (1) | KR101979042B1 (xx) |
| CN (1) | CN103958502B (xx) |
| BR (1) | BR112014002675A2 (xx) |
| CA (1) | CA2844058A1 (xx) |
| ES (1) | ES2552989T3 (xx) |
| HK (2) | HK1199021A1 (xx) |
| MX (1) | MX340756B (xx) |
| RU (1) | RU2014108140A (xx) |
| WO (1) | WO2013020062A1 (xx) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2013143839A (ru) | 2011-02-28 | 2015-04-10 | Эррэй Биофарма Инк. | Ингибиторы сериновых/треониновых киназ |
| WO2013020062A1 (en) | 2011-08-04 | 2013-02-07 | Array Biopharma Inc. | Quinazoline compounds as serine/threonine kinase inhibitors |
| RU2650501C2 (ru) | 2012-03-01 | 2018-04-16 | Эррэй Биофарма Инк. | Ингибиторы серин/треониновых киназ |
| CA2882750A1 (en) * | 2012-08-27 | 2014-03-06 | Jim Blake | Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases |
| MX2015004615A (es) | 2012-10-16 | 2015-07-17 | Hoffmann La Roche | Inhibidores de serina/treonina cinasa. |
| CN103254142B (zh) * | 2013-04-26 | 2015-10-28 | 浙江工业大学 | 4-[4-(2-取代氨基乙酰氨基)苯胺基]喹唑啉类衍生物及制备和应用 |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| KR102359759B1 (ko) | 2013-12-06 | 2022-02-09 | 제넨테크, 인크. | 세린/트레오닌 키나제 저해제 |
| KR102379517B1 (ko) | 2013-12-30 | 2022-03-25 | 제넨테크, 인크. | 세린/트레오닌 키나아제 억제제 |
| CN105980387B (zh) * | 2013-12-30 | 2019-04-19 | 阵列生物制药公司 | 丝氨酸/苏氨酸激酶抑制剂 |
| MX2016013027A (es) | 2014-04-04 | 2017-05-23 | Del Mar Pharmaceuticals | Uso de dianhidrogalactitol y analogos o derivados del mismo para tratar cancer de celulas no pequeñas del pulmon y cancer de ovario. |
| CA3018406A1 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| CN111373055A (zh) | 2017-09-08 | 2020-07-03 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
| US20210008047A1 (en) | 2018-02-13 | 2021-01-14 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| US11447493B2 (en) | 2018-05-02 | 2022-09-20 | Kinnate Biopharma Inc. | Inhibitors of cyclin-dependent kinases |
| SG11202013175SA (en) | 2018-06-29 | 2021-01-28 | Kinnate Biopharma Inc | Inhibitors of cyclin-dependent kinases |
| LT3873903T (lt) | 2018-10-31 | 2024-05-10 | Gilead Sciences, Inc. | Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai |
| US11071730B2 (en) | 2018-10-31 | 2021-07-27 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| CN115243687A (zh) * | 2019-10-25 | 2022-10-25 | 默沙东有限责任公司 | 作为lrrk2抑制剂的n-(杂芳基)喹唑啉-2-胺衍生物、药物组合物及其用途 |
| CN115448864B (zh) * | 2022-08-26 | 2023-12-22 | 上海方予健康医药科技有限公司 | 3-氟-3-（1-羟乙基）吡咯烷-1-羧酸叔丁酯的制备方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT672042E (pt) | 1993-10-01 | 2006-08-31 | Novartis Ag | Derivados de pirimidinoamina farmacologicamente activos e processos para a sua preparacao |
| US5612340A (en) | 1993-10-01 | 1997-03-18 | Ciba-Geigy Corporation | Pyrimidineamine derivatives and processes for the preparation thereof |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| CZ9902016A3 (cs) | 1996-12-05 | 1999-11-17 | Amgen Inc. | Substituované pyrimidinonové a pyridonové sloučeniny a způsoby jejich použití |
| US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
| ATE293962T1 (de) | 2000-02-25 | 2005-05-15 | Hoffmann La Roche | Adenosin-rezeptor modulatoren |
| DE60107835T2 (de) | 2000-04-26 | 2005-12-22 | Eisai Co., Ltd. | Medizinische zusammensetzungen zur förderung der aktivierung der eingeweide |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| MXPA04011470A (es) | 2002-05-21 | 2005-02-14 | Amgen Inc | Compuestos heterociclicos sustituidos y metodos de uso. |
| JP4530852B2 (ja) | 2002-07-15 | 2010-08-25 | メルク・シャープ・エンド・ドーム・コーポレイション | 糖尿病治療のためのピペリジノピリミジンジペプチジルペプチダーゼ阻害剤 |
| TW200533357A (en) | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| AU2005214159A1 (en) * | 2004-02-04 | 2005-09-01 | Pfizer Products Inc. | Substituted quinoline compounds |
| ATE485824T1 (de) | 2004-04-13 | 2010-11-15 | Icagen Inc | Polycyclische pyrimidine als kaliumionenkanal- modulatoren |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US20080187575A1 (en) | 2004-08-27 | 2008-08-07 | Bert Klebl | Pyrimidine Derivatives |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| JP2008536950A (ja) | 2005-04-18 | 2008-09-11 | ニューロジェン・コーポレーション | 置換ヘテロアリールのｃｂ１拮抗薬 |
| US7572809B2 (en) | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| JP2009528280A (ja) | 2006-02-16 | 2009-08-06 | シェーリング コーポレイション | Ｅｒｋインヒビターとしてのピロリジン誘導体 |
| WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| DE102006035202A1 (de) | 2006-07-29 | 2008-01-31 | Lanxess Deutschland Gmbh | Konservierungsmittel auf Basis von Carbonsäureanhydriden |
| ATE530540T1 (de) | 2006-08-23 | 2011-11-15 | Pfizer Prod Inc | Pyrimidonverbindungen als gsk-3-inhibitoren |
| WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| AU2007336933A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections |
| PT2200436E (pt) | 2007-09-04 | 2015-04-29 | Scripps Research Inst | Pirimidinilaminas substituídas como inibidoras da proteína quinase |
| KR20100088150A (ko) | 2007-11-06 | 2010-08-06 | 이 아이 듀폰 디 네모아 앤드 캄파니 | 살진균성 복소환식 아민 |
| US20090246198A1 (en) * | 2008-03-31 | 2009-10-01 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors and methods of use thereof |
| CA2986640C (en) | 2008-06-27 | 2019-03-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| BRPI0913966A2 (pt) | 2008-06-27 | 2015-11-17 | Novartis Ag | compostos orgânicos |
| PL2370413T3 (pl) | 2008-12-08 | 2016-01-29 | Arena Pharm Inc | Modulatory receptora prostacykliny (PGI2) użyteczne w leczeniu zaburzeń z nimi związanych |
| RU2013143839A (ru) * | 2011-02-28 | 2015-04-10 | Эррэй Биофарма Инк. | Ингибиторы сериновых/треониновых киназ |
| WO2013020062A1 (en) | 2011-08-04 | 2013-02-07 | Array Biopharma Inc. | Quinazoline compounds as serine/threonine kinase inhibitors |
| RU2650501C2 (ru) | 2012-03-01 | 2018-04-16 | Эррэй Биофарма Инк. | Ингибиторы серин/треониновых киназ |
| CA2882750A1 (en) | 2012-08-27 | 2014-03-06 | Jim Blake | Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases |
-
2012
- 2012-08-03 WO PCT/US2012/049551 patent/WO2013020062A1/en active Application Filing
- 2012-08-03 EP EP12769775.3A patent/EP2739618B1/en active Active
- 2012-08-03 ES ES12769775.3T patent/ES2552989T3/es active Active
- 2012-08-03 KR KR1020147005731A patent/KR101979042B1/ko active IP Right Grant
- 2012-08-03 RU RU2014108140/04A patent/RU2014108140A/ru not_active Application Discontinuation
- 2012-08-03 JP JP2014524111A patent/JP6097289B2/ja active Active
- 2012-08-03 CA CA2844058A patent/CA2844058A1/en not_active Abandoned
- 2012-08-03 MX MX2014001389A patent/MX340756B/es active IP Right Grant
- 2012-08-03 BR BR112014002675A patent/BR112014002675A2/pt not_active IP Right Cessation
- 2012-08-03 CN CN201280049268.3A patent/CN103958502B/zh active Active
- 2012-08-03 US US14/237,143 patent/US9187462B2/en active Active
-
2014
- 2014-12-10 HK HK14112451.1A patent/HK1199021A1/xx unknown
- 2014-12-19 HK HK14112740.2A patent/HK1199248A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101979042B1 (ko) | 2019-05-15 |
| BR112014002675A2 (pt) | 2017-02-21 |
| CN103958502B (zh) | 2016-02-10 |
| EP2739618B1 (en) | 2015-09-16 |
| CN103958502A (zh) | 2014-07-30 |
| MX340756B (es) | 2016-07-25 |
| HK1199248A1 (zh) | 2015-06-26 |
| ES2552989T3 (es) | 2015-12-03 |
| JP6097289B2 (ja) | 2017-03-15 |
| CA2844058A1 (en) | 2013-02-07 |
| EP2739618A1 (en) | 2014-06-11 |
| KR20140062057A (ko) | 2014-05-22 |
| JP2014521696A (ja) | 2014-08-28 |
| MX2014001389A (es) | 2014-11-13 |
| RU2014108140A (ru) | 2015-09-10 |
| US9187462B2 (en) | 2015-11-17 |
| US20150087664A1 (en) | 2015-03-26 |
| WO2013020062A1 (en) | 2013-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1254429A1 (zh) | 絲氨酸/蘇氨酸激酶抑制劑 | |
| IL265007B (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
| HK1199248A1 (zh) | 作為絲氨酸/蘇氨酸激酶抑制劑的喹唑啉化合物 | |
| HK1215253A1 (zh) | 作為激酶抑制劑的吡咯並嘧啶化合物 | |
| IL227399A0 (en) | Novel azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors | |
| HK1192247A1 (zh) | 作為激酶抑制劑的雜環化合物 | |
| HK1199880A1 (en) | Benzonitrile derivatives as kinase inhibitors | |
| IL228103A0 (en) | Amino-quinolines as kinase inhibitors | |
| HK1211574A1 (en) | Serine threonine kinase inhibitors | |
| EP2685992A4 (en) | AMINO-QUINOLINES AS KINASE INHIBITORS |